Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Castle Biosciences gets ccreditation from College of American Pathology » 07:07
11/21/22
11/21
07:07
11/21/22
07:07
CSTL

Castle Biosciences

$21.06 /

+1.14 (+5.72%)

Castle Biosciences …

Castle Biosciences announced that the Accreditation Committee of the College of American Pathologists has accredited its clinical laboratory facility in Pittsburgh. This achievement follows a recent on-site inspection as part of the CAP's Laboratory Accreditation Program. "This important accreditation is reflective of Castle's commitment to excellence, safety and quality, driven by our dedicated laboratory team," said Kristen Oelschlager, chief operating officer of Castle Biosciences. "We are proud that clinicians and patients can use our innovative tests knowing that our clinical laboratories have received this accreditation reserved for laboratories operating under the high standards required by CAP."

ShowHide Related Items >><<
CSTL Castle Biosciences
$21.06 /

+1.14 (+5.72%)

CSTL Castle Biosciences
$21.06 /

+1.14 (+5.72%)

11/03/22 Baird
Castle Biosciences price target lowered to $41 from $48 at Baird
08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
CSTL Castle Biosciences
$21.06 /

+1.14 (+5.72%)

Hot Stocks
Castle Biosciences: DecisionDx -SCC test adds clarity in ambiguos situations » 07:38
11/15/22
11/15
07:38
11/15/22
07:38
CSTL

Castle Biosciences

$22.51 /

+0.01 (+0.04%)

Castle Biosciences…

Castle Biosciences announced new data showing how the Company's DecisionDx -SCC test can provide objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma, cSCC, tumors with uncertainty in differentiation status. The data were shared in an oral presentation given at the American Society of Dermatopathology ASDP 59th Annual Meeting by Sarah Estrada, M.D., dermatopathologist with Affiliated Dermatology in Scottsdale, Arizona. Overall, these data demonstrate how DecisionDx-SCC can significantly stratify the risk of metastasis in high-risk cSCC patients with an ambiguous tumor differentiation status. Additionally, the study suggests that incorporating the test's results into clinical cSCC risk assessments could improve risk-stratification and enhance current patient management decisions to improve patient outcomes. Subjective pathology variability in the histologic grading of cSCC tumors is an important clinical issue, particularly when comparing moderately differentiated tumors. Poor differentiation has been shown to be an independent risk factor associated with poor patient outcomes.1-3 However, there is a lack of consistency in differentiation assessment4 which can adversely impact the value of differentiation as a prognostic factor. In fact, the two most widely used cSCC staging systems, American Joint Committee on Cancer Staging Manual Eighth Edition and Brigham and Women's Hospital , vary on their inclusion of poor differentiation as a risk factor for staging; BWH includes it, while AJCC8 does not. "A single clinicopathologic risk factor, including a cSCC tumor's differentiation status, can affect staging and thereby escalate or deescalate patient treatment plans," commented Estrada. "Objective risk-stratification that is independent of clinicopathologic factors and staging, as provided by DecisionDx-SCC test results, can identify high-risk cSCC lesions and provide clarity in challenging staging situations."

ShowHide Related Items >><<
CSTL Castle Biosciences
$22.51 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$22.51 /

+0.01 (+0.04%)

11/03/22 Baird
Castle Biosciences price target lowered to $41 from $48 at Baird
08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
CSTL Castle Biosciences
$22.51 /

+0.01 (+0.04%)

Over a month ago
Recommendations
Castle Biosciences price target lowered to $41 from $48 at Baird » 06:44
11/03/22
11/03
06:44
11/03/22
06:44
CSTL

Castle Biosciences

$24.80 /

-0.98 (-3.80%)

Baird analyst Catherine…

Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Castle Biosciences to $41 from $48 and keeps an Outperform rating on the shares. The analyst noted they reported a strong 3Q, with revenue coming in above Street and tey again raised its 2022 revenue outlook. She also noted volumes came in slightly below hermodel, but ASP upside drove the revenue beat.

ShowHide Related Items >><<
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

Earnings
Castle Biosciences raises FY22 revenue view to $132M-$137M from $130M-$135M  16:41
11/02/22
11/02
16:41
11/02/22
16:41
CSTL

Castle Biosciences

$24.80 /

-0.98 (-3.80%)

Consensus $132.3M

ShowHide Related Items >><<
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

Earnings
Castle Biosciences reports Q3 EPS (77c), consensus (88c) » 16:40
11/02/22
11/02
16:40
11/02/22
16:40
CSTL

Castle Biosciences

$24.80 /

-0.98 (-3.80%)

Reports Q3 revenue…

Reports Q3 revenue $37.0M, consensus $34.8M. "We achieved strong top-line growth and a new record in total quarterly test report volume, which we believe was due to continued strong execution from the Castle team, despite typical seasonality," said Derek Maetzold, CEO of Castle Biosciences. "We believe that our portfolio of innovative tests brings substantial added value to clinicians and their patients. Further, we believe our tests enable shared and informed treatment decisions that improve patient outcomes, and we expect they will continue to prove their clinical utility in the marketplace and build momentum. Our strategic growth initiatives, specifically the acquisitions and integrations of TissueCypher(R) and IDgenetix(R), are progressing as expected. We are pleased with the results from these franchises to date. The addition of these two tests was intended to provide material revenue in 2024 and beyond. We believe the expected growth from these acquisitions, coupled with our expectation for continued strong organic revenue, should position us well for long-term value creation for stockholders."

ShowHide Related Items >><<
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$24.80 /

-0.98 (-3.80%)

Hot Stocks
Castle Biosciences announces new TissueCypher Barrett's Esophagus Test results » 07:19
10/25/22
10/25
07:19
10/25/22
07:19
CSTL

Castle Biosciences

$20.32 /

-1.25 (-5.80%)

Castle Biosciences…

Castle Biosciences announced new data showing that the use of TissueCypher Barrett's Esophagus Test results can significantly improve management decisions for Barrett's esophagus, or BE, patients with low-grade dysplasia, or LGD, to improve health outcomes. TissueCypher is Castle's precision medicine test designed to predict future development of high-grade dysplasia, or HGD, and/or esophageal adenocarcinoma, or EAC, within five years for patients diagnosed with BE. Overall, the study results suggest that TissueCypher may be used to standardize the management of BE patients with LGD to improve health outcomes, by helping ensure that patients at a high risk of progression receive earlier interventions and by potentially reducing unnecessary use of endoscopic eradication therapy, or EET, and endoscopies for lower risk patients. The study results were shared in a podium presentation at the 2022 American College of Gastroenterology Annual Scientific Meeting, being held October 21-26 in Charlotte, North Carolina. The study involved a cohort of 154 real patients with known outcomes who were followed prospectively as part of the SURF trial. Twenty-four of these patients progressed to HGD/EAC within five years. Each patient's baseline specimens were independently reviewed by 30 pathologists from five countries and also tested with TissueCypher in a blinded manner. Management decision simulations were performed, where each patient's baseline specimens were first evaluated by a generalist pathologist, and then referred to an expert pathologist from the same country for any diagnoses of LGD. In one arm of the study, management for the patients was determined by the current standard of care, which includes pathology review of tissue samples and management according to current guidelines. In the other arm, patients were managed by the current standard of care with additional guidance from TissueCypher test results. The percentage of patients receiving appropriate management per their known outcome was compared between the two study arms, with appropriate management defined as: Three- to five-year surveillance for patients who did not progress to HGD/EAC during surveillance; and Either surveillance in less than one year or EET for patients who did progress to HGD/EAC during surveillance. The study results showed the following: Using TissueCypher test results to guide patient management decisions significantly increased the likelihood of BE patients with LGD receiving appropriate management per their known outcome. 58.4% of patients had a 100% chance of receiving appropriate management when TissueCypher test results were used to guide decisions despite different pathologists reviewing their baseline specimens, compared to 9.1% of patients who were managed according to the standard of care pathology review alone. Use of TissueCypher test results improved the consistency of management decisions for BE patients with LGD by reducing the impact of variable pathology review. 57.1% of patients whose care was guided with the addition of TissueCypher test results had no deviation in management decisions when different pathologists reviewed their baseline specimens, compared to 7.1% of patients whose management was guided only by the current standard of care.

ShowHide Related Items >><<
CSTL Castle Biosciences
$20.32 /

-1.25 (-5.80%)

CSTL Castle Biosciences
$20.32 /

-1.25 (-5.80%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$20.32 /

-1.25 (-5.80%)

Hot Stocks
Castle Biosciences announces new data from DECIDE study » 17:02
10/20/22
10/20
17:02
10/20/22
17:02
CSTL

Castle Biosciences

$21.78 /

-0.09 (-0.41%)

Castle Biosciences…

Castle Biosciences announced new data from its prospective, multicenter DECIDE study in which DecisionDx-Melanoma test results influenced 85% of clinicians' decisions regarding the sentinel lymph node biopsy surgical procedure, demonstrating the role of the test's results in guiding risk-aligned patient management decisions. "Melanoma is an aggressive and deadly disease, thus any decisions on whether to forego a procedure like an SLNB cannot be taken lightly," said J. Michael Guenther, M.D., surgical oncologist at St. Elizabeth Physicians in Edgewood, Kentucky. "The clinically actionable information that DecisionDx-Melanoma provides is precious to both doctors and patients. It enables me to have more productive conversations with my patients, so we can make shared, informed decisions about their overall care; this includes decisions on whether to pursue an SLNB if their risk of a positive sentinel lymph node is low."

ShowHide Related Items >><<
CSTL Castle Biosciences
$21.78 /

-0.09 (-0.41%)

CSTL Castle Biosciences
$21.78 /

-0.09 (-0.41%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$21.78 /

-0.09 (-0.41%)

Hot Stocks
Castle Biosciences to give data supporting value of skin cancer tests at ASDS » 07:04
10/10/22
10/10
07:04
10/10/22
07:04
CSTL

Castle Biosciences

$26.52 /

-1.15 (-4.16%)

Castle Biosciences is…

Castle Biosciences is presenting data highlighting its portfolio of skin cancer gene expression profile GEP tests at the 2022 American Society for Dermatologic Surgery ASDS Annual Meeting, being held Oct. 6-10 in Aurora, Colorado, including new data highlighting impactful changes in risk-aligned patient management strategies after clinicians received DecisionDx -SCC test results. DecisionDx-SCC is Castle's prognostic 40-GEP test designed to use a patient's tumor biology to predict individual risk of metastasis for patients diagnosed with cutaneous squamous cell carcinoma SCC who have one or more high-risk factors. The test stratifies patients into one of three classes based on their biologic risk of metastasis: Class 1 , Class 2A or Class 2B .

ShowHide Related Items >><<
CSTL Castle Biosciences
$26.52 /

-1.15 (-4.16%)

CSTL Castle Biosciences
$26.52 /

-1.15 (-4.16%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$26.52 /

-1.15 (-4.16%)

Conference/Events
Castle Biosciences management to meet with Lake Street » 07:31
10/04/22
10/04
07:31
10/04/22
07:31
CSTL

Castle Biosciences

$27.76 /

+1.56 (+5.95%)

Meetings to be held in…

Meetings to be held in Denver on October 3 and in Salt Lake City on October 4 hosted by Lake Street.

ShowHide Related Items >><<
CSTL Castle Biosciences
$27.76 /

+1.56 (+5.95%)

CSTL Castle Biosciences
$27.76 /

+1.56 (+5.95%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$27.76 /

+1.56 (+5.95%)

CSTL Castle Biosciences
$27.76 /

+1.56 (+5.95%)

Hot Stocks
Castle Biosciences announces publication of DecisionDx-Melanoma data » 07:12
09/23/22
09/23
07:12
09/23/22
07:12
CSTL

Castle Biosciences

$25.00 /

-1.65 (-6.19%)

Castle Biosciences…

Castle Biosciences announced the publication of a study in the Journal of the American Academy of Dermatology validating the performance of DecisionDx-Melanoma's proprietary algorithm, i31-ROR. i31-ROR is designed to integrate a patient's tumor biology with clinicopathologic factors to provide the patient's personalized risk of melanoma recurrence. The study, accessible here, found that DecisionDx-Melanoma's integrated algorithms provide more precise risk-stratification and individualized risk estimates, compared to those based on clinicopathologic factors alone, and can ultimately improve treatment decisions. As expected in the study, the most significant factor in predicting melanoma-specific survival was the tumor biology risk as identified by DecisionDx-Melanoma's 31-gene expression profile. Additionally, DecisionDx-Melanoma, including both algorithms, identified 44% of patients who could potentially forego the sentinel lymph node biopsy surgical procedure while maintaining high survival rates or were re-stratified as being at a higher or lower risk of recurrence or death than initially staged using the American Joint Committee on Cancer 8th edition staging criteria.

ShowHide Related Items >><<
CSTL Castle Biosciences
$25.00 /

-1.65 (-6.19%)

CSTL Castle Biosciences
$25.00 /

-1.65 (-6.19%)

08/09/22 Baird
Castle Biosciences price target raised to $48 from $44 at Baird
05/19/22 Baird
Baird says final LCD for test 'incrementally positive' for Castle Biosciences
05/10/22 Canaccord
Castle Biosciences price target lowered to $65 from $80 at Canaccord
05/10/22 Baird
Castle Biosciences price target lowered to $44 from $50 at Baird
CSTL Castle Biosciences
$25.00 /

-1.65 (-6.19%)

CSTL Castle Biosciences
$25.00 /

-1.65 (-6.19%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.